Jeffrey Smith - Alder BioPharmaceutica Senior Vice President Translational Medicine
President
Dr. Jeffrey T.L. Smith, M.D., is Managing Director of the Company., a subsidiary of the Company. Dr. Smith has served as our Managing Director of Alder Biopharmaceuticals Limited since March 2017. Dr. Smith previously served as our Senior Vice President, Translational Medicine from 2012 to March 2017 and in other senior management positions from April 2004 to 2012. From 1999 to 2004, Dr. Smith served as Senior Director of Medical Research for Celltech RD, where he was responsible for planning and managing the CDP870 antiTNF clinical trials for rheumatoid arthritis as well as several other key autoimmune clinical development programs. From 1997 to 1999, Dr. Smith served as Medical Director at Simbec Research Ltd., a contract research organization. From 1995 to 1997, Dr. Smith served as Head of Clinical Pharmacology at Hoechst Marion Roussel Ltd., a pharmaceutical company. From 1994 to 1995, Dr. Smith served as a Senior Clinical Physician at the Proctor and Gamble Company, a publiclytraded consumer products company, and from 1989 to 1994, he served as a Senior Research Physician in the clinical pharmacology department at Glaxo Research and Development Ltd., now a division of GlaxoSmithKline plc. Dr. Smith holds an M.D. from the University of London and is a Fellow of the Royal College of Physicians in London. since 2017.
| Age | 58 |
| Tenure | 7 years |
| Phone | 425 205-2900 |
| Web | www.alderbio.com |
Jeffrey Smith Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jeffrey Smith against Alder BioPharmaceutica stock is an integral part of due diligence when investing in Alder BioPharmaceutica. Jeffrey Smith insider activity provides valuable insight into whether Alder BioPharmaceutica is net buyers or sellers over its current business cycle. Note, Alder BioPharmaceutica insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alder BioPharmaceutica'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jeffrey Smith over three weeks ago Acquisition by Jeffrey Smith of 2 shares of Midland States subject to Rule 16b-3 | ||
Jeffrey Smith over three weeks ago Acquisition by Jeffrey Smith of 148 shares of Midland States subject to Rule 16b-3 |
Alder BioPharmaceutica Management Efficiency
The company has return on total asset (ROA) of (100.8551) % which means that it has lost $100.8551 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4193) %, meaning that it created substantial loss on money invested by shareholders. Alder BioPharmaceutica's management efficiency ratios could be used to measure how well Alder BioPharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 193.36 M in liabilities with Debt to Equity (D/E) ratio of 89.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alder BioPharmaceuticals has a current ratio of 8.76, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alder BioPharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Alder BioPharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alder BioPharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alder to invest in growth at high rates of return. When we think about Alder BioPharmaceutica's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 8 records | PRESIDENT Age | ||
| Robin Gibbs | Siriuspoint | 49 | |
| Prashanth Gangu | Siriuspoint | 40 | |
| Ryan Bell | Encore Capital Group | 44 | |
| Andrew Wise | Arrow Financial | 57 | |
| Terry Goodemote | Arrow Financial | 50 | |
| Edward Campanella | Arrow Financial | 50 | |
| Paul Grinberg | Encore Capital Group | 56 | |
| Thomas Lauer | Fidus Investment Corp | 56 | |
Management Performance
| Return On Equity | -1.42 | |||
| Return On Asset | -100.86 |
Alder BioPharmaceuticals Leadership Team
Elected by the shareholders, the Alder BioPharmaceutica's board of directors comprises two types of representatives: Alder BioPharmaceutica inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alder. The board's role is to monitor Alder BioPharmaceutica's management team and ensure that shareholders' interests are well served. Alder BioPharmaceutica's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alder BioPharmaceutica's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erin Lavelle, COO | ||
| Xavier GallotLavallee, Member of the Supervisory Board | ||
| Deepa Pakianathan, Independent Director | ||
| Bruce Montgomery, Independent Director | ||
| Paul Streck, Chief Medical Officer | ||
| Anne TrotouxCoppermann, Member of the Supervisory Board | ||
| Robert Azelby, President CEO | ||
| Christian Viguie, Chairman of the Supervisory Board | ||
| Deepika Pakianathan, Independent Director | ||
| John Latham, Co-Founder and Chief Scientific Officer | ||
| Jeremy Green, Director | ||
| Bruno Pavlovsky, Member of the Supervisory Board | ||
| Wendy Yarno, Independent Director | ||
| Joel Desmaris, Member of the Management Board in Charge of Finance and Investor Relations | ||
| Olivier Lambert, Member of the Supervisory Board | ||
| Randal Hassler, Senior Vice President Pharmaceutical Operations | ||
| Paul Carter, Director | ||
| Stephen Dow, Independent Chairman of the Board | ||
| Randall Schatzman, Co-Founder, CEO and President and Director | ||
| Eric Carter, Interim Chief Medical Officer | ||
| Nadia Dac, Chief Commercial Officer | ||
| Mark Litton, Chief Business Officer, Treasurer and Secretary | ||
| Larry Benedict, Sr. VP of Fin. | ||
| Carlos Campoy, CFO | ||
| Pierre Conte, Member of the Supervisory Board | ||
| Pierre Tourrette, Vice Chairman of the Supervisory Board | ||
| Heather Preston, Independent Director | ||
| Jeffrey Smith, Senior Vice President Translational Medicine | ||
| Timothy Whitaker, Chief Medical Officer | ||
| James Bucher, Senior Vice President General Counsel | ||
| Paul Cleveland, Director | ||
| Clay Siegall, Independent Director | ||
| Frederic Serre, Chairman of the Management Board | ||
| Elisabeth Sandoval, Chief Commercial Officer | ||
| Philippe Mattia, Member of the Supervisory Board |
Alder Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alder BioPharmaceutica a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.42 | |||
| Return On Asset | -100.86 | |||
| Profit Margin | 15.82 % | |||
| Operating Margin | (7.69) % | |||
| Current Valuation | 1.46 B | |||
| Shares Outstanding | 83.64 M | |||
| Shares Owned By Insiders | 5.20 % | |||
| Shares Owned By Institutions | 94.80 % | |||
| Number Of Shares Shorted | 12.05 M | |||
| Price To Earning | (2.18) X |
Pair Trading with Alder BioPharmaceutica
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alder BioPharmaceutica position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alder BioPharmaceutica will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to PerkinElmer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace PerkinElmer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back PerkinElmer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling PerkinElmer to buy it.
The correlation of PerkinElmer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as PerkinElmer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if PerkinElmer moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for PerkinElmer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Alder BioPharmaceuticals information on this page should be used as a complementary analysis to other Alder BioPharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Alder Stock
If you are still planning to invest in Alder BioPharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Alder BioPharmaceutica's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |